JNJ

227.25

-0.15%↓

UNH

370.37

+1.02%↑

TMO

465.89

-0.95%↓

ISRG

452.38

-3.02%↓

ABT

91.51

-2.44%↓

JNJ

227.25

-0.15%↓

UNH

370.37

+1.02%↑

TMO

465.89

-0.95%↓

ISRG

452.38

-3.02%↓

ABT

91.51

-2.44%↓

JNJ

227.25

-0.15%↓

UNH

370.37

+1.02%↑

TMO

465.89

-0.95%↓

ISRG

452.38

-3.02%↓

ABT

91.51

-2.44%↓

JNJ

227.25

-0.15%↓

UNH

370.37

+1.02%↑

TMO

465.89

-0.95%↓

ISRG

452.38

-3.02%↓

ABT

91.51

-2.44%↓

JNJ

227.25

-0.15%↓

UNH

370.37

+1.02%↑

TMO

465.89

-0.95%↓

ISRG

452.38

-3.02%↓

ABT

91.51

-2.44%↓

Home・Akciju saraksts・Smith & Nephew PLC ADR

Smith & Nephew PLC ADR

Slēgts

30.38 -2.25

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

30.34

Max

31.06

Galvenie mērījumi
By Trading Economics
Ienākumi	35M 331M
Pārdošana	203M 3.2B
P/E Sektora vidējais	22.441 67.147
Dividenžu ienesīgums	2.44
Peļņas marža	10.368
Darbinieki	16,988
EBITDA	133M 856M

Rekomendācijas
By TipRanks
Rekomendācijas	Neitrāls
Prognoze 12 mēnešiem	+2.96% upside

Dividendes
By Dow Jones
Dividenžu ienesīgums Sektora vidējais	2.44% 2.36%

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-1.5B 14B
Iepriekšējā atvēršanas cena	32.63
Iepriekšējā slēgšanas cena	30.38

Tehniskais rādītājs

By Trading Central

Pārliecība

Bullish Evidence

26.64 / 28.37 Atbalsts un pretestība

Smith & Nephew PLC ADR Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 29. apr. 23:53 UTC

Peļņas

Naver Posts Weaker First-Quarter Earnings

2026. g. 29. apr. 23:41 UTC

Karstas akcijas

Stocks to Watch: Meta Platforms, Alphabet, Qualcomm, Amazon.com

2026. g. 29. apr. 23:55 UTC

Peļņas

Samsung Electronics 1Q Net Profit Beat FactSet-Compiled Consensus

2026. g. 29. apr. 23:54 UTC

Peļņas

Samsung Electronics 1Q Net KRW47.225T Vs. Net KRW8.223T >005930.SE

2026. g. 29. apr. 23:52 UTC

Peļņas

Samsung Electronics 1Q Oper Pft KRW57.233T Vs. Pft KRW6.685T >005930.SE

2026. g. 29. apr. 23:51 UTC

Peļņas

Samsung Electronics 1Q Rev KRW133.873T Vs. KRW79.141T >005930.SE

2026. g. 29. apr. 23:51 UTC

Tirgus saruna

Nikkei May Fall Amid Uncertainty Over Mideast Conflict -- Market Talk

2026. g. 29. apr. 23:34 UTC

Tirgus saruna

Gold Edges Higher on Likely Technical Recovery -- Market Talk

2026. g. 29. apr. 23:24 UTC

Peļņas

CSC Financial 1Q Results Supported By Higher Income From Fees, Commission>6066.HK

2026. g. 29. apr. 23:24 UTC

Peļņas

CSC Financial Gains From Changes in Fair Value on Financial Assets Also Aided Results>6066.HK

2026. g. 29. apr. 23:24 UTC

Peļņas

CSC Financial 1Q Net CNY3.67B Vs. Net CNY1.84B >6066.HK

2026. g. 29. apr. 23:24 UTC

Peļņas

CSC Financial 1Q Rev CNY7.70B Vs. CNY4.74B >6066.HK

2026. g. 29. apr. 23:22 UTC

Peļņas

China Longyuan 1Q Net CNY1.70B, Down 14%

2026. g. 29. apr. 23:22 UTC

Peļņas

China Longyuan: Power Generation Down 2.9% as of End-March

2026. g. 29. apr. 23:20 UTC

Peļņas

China Longyuan: 1Q Rev From Wind Power Fell, Rev From Solar Power Rose

2026. g. 29. apr. 23:20 UTC

Peļņas

China Longyuan 1Q Rev CNY7.87B, Down 3.6%

2026. g. 29. apr. 23:19 UTC

Peļņas

China Vanke 1Q Loss CNY5.95B Vs. Loss CNY6.25B >000002.SZ

2026. g. 29. apr. 23:19 UTC

Peļņas

China Vanke: Weak China Real Estate Market Continue to Weigh on Results>000002.SZ

2026. g. 29. apr. 23:19 UTC

Peļņas

China Vanke 1Q Rev CNY28.93B Vs. CNY37.99B >000002.SZ

2026. g. 29. apr. 23:19 UTC

Peļņas

China Vanke 1Q Loss Narrows>000002.SZ

2026. g. 29. apr. 23:18 UTC

Peļņas

Naver1Q Net Profit Missed FactSet-Compiled Consensus

2026. g. 29. apr. 23:17 UTC

Peļņas

Naver 1Q Net KRW291.00B Vs. Net KRW423.70B >035420.SE

2026. g. 29. apr. 23:15 UTC

Peļņas

Naver 1Q Oper Pft KRW541.80B Vs. Pft KRW505.30B >035420.SE

2026. g. 29. apr. 23:15 UTC

Peļņas

Naver 1Q Rev KRW3.241T Vs. KRW2.787T >035420.SE

2026. g. 29. apr. 23:13 UTC

Peļņas

CICC: Gains From Investments in Financial Instruments Also Aided Results >3908.HK

2026. g. 29. apr. 23:12 UTC

Peļņas

CICC Results Supported by Increase in Fee, Commission Income >3908.HK

2026. g. 29. apr. 23:11 UTC

Peļņas

CICC 1Q Rev CNY8.83B Vs. CNY5.72B >3908.HK

2026. g. 29. apr. 23:11 UTC

Peļņas

CICC 1Q Net CNY3.58B Vs. Net CNY2.04B >3908.HK

2026. g. 29. apr. 23:04 UTC

Peļņas

Microsoft Reports Strong Cloud Growth, but Questions About AI Returns Persist -- WSJ

2026. g. 29. apr. 23:04 UTC

Peļņas

Meta Reports Big Revenue Jump and Projected Spending Increase -- 3rd Update

Salīdzinājums

Cenas izmaiņa

Smith & Nephew PLC ADR Prognoze

Cenas mērķis

By TipRanks

2.96% augšup

Prognoze 12 mēnešiem

Vidējais 32 USD 2.96%

Augstākais 32 USD

Zemākais 32 USD

Pamatojoties uz 1 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Smith & Nephew PLC ADR — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Neitrāls

1 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 1 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Smith & Nephew PLC ADR — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

26.64 / 28.37Atbalsts un pretestība

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Smith & Nephew PLC ADR

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.